Soluble Interleukin-13Rα2 Decoy Receptor Inhibits Hodgkin’s Lymphoma Growthin Vitroandin Vivo
- 1 May 2004
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 64 (9) , 3271-3275
Abstract
Recent studies have demonstrated that the malignant Reed-Sternberg cells of Hodgkin’s lymphoma (HL) secrete and are responsive to interleukin (IL)-13. We hypothesized that overexpression of a soluble IL-13 decoy receptor (sIL-13Rα2) via adenoviral-mediated gene transfer would inhibit IL-13-induced Reed-Sternberg cell proliferation. Western blot and ELISA analysis verified expression of sIL-13Rα2 in cell lysates and supernatants of AdsIL-13Rα2-transduced COS-7 cells. Treatment of two IL-13-responsive HL-derived cell lines, HDLM-2 and l-1236, with AdsIL-13Rα2-conditioned medium, resulted in the inhibition of cell proliferation, and down-regulated the phosphorylation of signal transducer and activator of transcription 6 (STAT6), an important mediator of IL-13 signaling. i.v. delivery of AdsIL-13Rα2 in NOD/SCID mice with s.c. implanted HDLM-2 cells delayed tumor onset and growth while enhancing survival compared with control mice. Intratumoral administration of AdsIL-13Rα2 led to the regression or stabilization of established tumors and was associated with diminished STAT6 phosphorylation. Our data demonstrate that AdsIL-13Rα2 can suppress HL growth in vitro and in vivo.Keywords
This publication has 33 references indexed in Scilit:
- Enhanced Interleukin (IL)-13 Responses in Mice Lacking IL-13 Receptor α 2Journal of Experimental Medicine, 2003
- Regulation and Function of the Interleukin 13 Receptor α 2 During a T Helper Cell Type 2–dominant Immune ResponseJournal of Experimental Medicine, 2003
- Expression of Interleukin 13 Receptor in Glioma and Renal Cell Carcinoma: IL13Rα2 as a Decoy Receptor for IL13Laboratory Investigation, 2001
- The interleukin-13 receptor α2 chain: an essential component for binding and internalization but not for interleukin-13–induced signal transduction through the STAT6 pathwayBlood, 2001
- An IL-13 inhibitor blocks the development of hepatic fibrosis during a T-helper type 2–dominated inflammatory responseJournal of Clinical Investigation, 1999
- cDNA Cloning and Characterization of the Human Interleukin 13 Receptor α ChainJournal of Biological Chemistry, 1996
- Cloning and Characterization of a Specific Interleukin (IL)-13 Binding Protein Structurally Related to the IL-5 Receptor α ChainJournal of Biological Chemistry, 1996
- Pathology of Hodgkinʼs diseaseCurrent Opinion in Oncology, 1994
- Interleukin 13, an interleukin 4-like cytokine that acts on monocytes and B cells, but not on T cellsImmunology Today, 1994
- lnterleukin-13 is a new human lymphokine regulating inflammatory and immune responsesNature, 1993